Aclaris Therapeutics (ACRS) Consolidated Net Income (2014 - 2026)

Aclaris Therapeutics' Consolidated Net Income history runs 13 years deep, the most recent figure standing at -$20.7 million for Q1 2026.

• In Q1 2026, Consolidated Net Income fell 29.9% year-over-year to -$20.7 million; the TTM figure through Mar 2026 stood at -$73.5 million (up 44.72% YoY), while the FY2025 annual figure was -$68.7 million, up 47.95% from the prior year.
• Consolidated Net Income was -$20.7 million for Q1 2026 at Aclaris Therapeutics, up from -$21.1 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$1.9 million in Q4 2023 to a low of -$97.6 million in Q4 2024.
• Historically, Consolidated Net Income has averaged -$23.9 million across 5 years, with a median of -$20.7 million in 2026.
• The sharpest annual moves came in 2023 and 2024: Consolidated Net Income surged 93.61% in 2023, then slumped 5151.45% in 2024.
• A 5-year view of Consolidated Net Income shows it stood at -$29.1 million in 2022, then soared by 93.61% to -$1.9 million in 2023, then plunged by 5151.45% to -$97.6 million in 2024, then surged by 78.37% to -$21.1 million in 2025, then increased by 2.0% to -$20.7 million in 2026.
• The last three Consolidated Net Income figures came in at -$20.7 million (Q1 2026), -$21.1 million (Q4 2025), and -$15.3 million (Q3 2025), per Business Quant data.